Cardiovascular and heart failure outcomes with type 2 diabetes therapies: how important is weight loss?

With the availability of GLP-1 receptor agonists and SGLT2 inhibitors, the null hypothesis of a neutral effect of diabetes therapy on macrovascular complications has been rejected. Cardiovascular outcome trials and several meta-analyses have consistently showed that these drugs, mostly in secondary prevention, decrease major adverse cardiovascular events (MACE), cardiovascular mortality, all-cause mortality, and hospital admission for heart...